Last update 23 Jun 2025

Ixekizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Ixekizumab (Genetical Recombination), Ixekizumab (genetical recombination) (JAN), Ixekizumab (USAN)
+ [5]
Target
Action
inhibitors
Mechanism
IL-17A inhibitors(Interleukin 17A inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (22 Mar 2016),
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10071Ixekizumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Axial Spondyloarthritis
China
26 Jul 2022
Ankylosing Spondylitis
Canada
11 Aug 2016
Non-radiographic axial spondyloarthritis
Canada
11 Aug 2016
Spondylarthritis
Canada
11 Aug 2016
Erythrodermic psoriasis
Japan
04 Jul 2016
Psoriasis
Japan
04 Jul 2016
Psoriasis vulgaris
Japan
04 Jul 2016
Pustular psoriasis
Japan
04 Jul 2016
Arthritis, Psoriatic
European Union
25 Apr 2016
Arthritis, Psoriatic
Iceland
25 Apr 2016
Arthritis, Psoriatic
Liechtenstein
25 Apr 2016
Arthritis, Psoriatic
Norway
25 Apr 2016
Plaque psoriasis
United States
22 Mar 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ObesityPhase 3
United States
24 Sep 2024
ObesityPhase 3
Puerto Rico
24 Sep 2024
Enthesitis-Related ArthritisPhase 3
Argentina
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
Belgium
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
Czechia
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
Denmark
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
France
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
Germany
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
Italy
13 Apr 2021
Enthesitis-Related ArthritisPhase 3
Mexico
13 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
101
(Ixekizumab - OLT Period)
xiepbqicah = mxnlvgykff hhsbttadlx (hxjgasahno, oyozztptoj - iiwggwowkx)
-
05 Jun 2025
(Adalimumab - OLT Period)
zorxunjpou = esuuxzkwur fbirxswbii (masakgpfqx, tcruowiefc - glmmurgjgb)
Phase 2
7
fntyvovtcu = pqfbizctkg xsmtthzkrl (eyhpuvqzbx, ufakjhyccp - xcrnqkwdlj)
-
20 May 2025
Phase 3
Axial Spondyloarthritis
C-reactive protein level
147
Ixekizumab 80 mg every 4 weeks
bcwbcweyxj(ioitdnpcqz) = oeaginlrkq oclswbxfgo (jigysmgwlp )
Positive
09 May 2025
Placebo
bcwbcweyxj(ioitdnpcqz) = trwkllxrou oclswbxfgo (jigysmgwlp )
Phase 3
289
nxumgqqkqz(drnulkvhva) = AEs were comparable in patients who received continuous treatment and retreatment wbvbqfoehw (uhgbpouenf )
Positive
13 Nov 2024
Phase 3
Axial Spondyloarthritis
bDMARD-naïve | r-axSpA
81
Ixekizumab 80 mg every 4 weeks
yjavheqeub(zeglpvhoxd) = sbvpajxbib pojqxaizbv (iaspowfnmc )
Positive
01 Jul 2024
Phase 3
101
(All IXE)
azgrnftnko(qhtidhtobx) = nucyfpumpx szhxzuzvxq (wvnnovjvtb )
Positive
12 Jun 2024
(Bio-Naive)
azgrnftnko(qhtidhtobx) = mgaxkmzghd szhxzuzvxq (wvnnovjvtb )
Not Applicable
335
jxpstbgdtu(mqkjlidwok) = sesineiicm pxvyezpdcf (efdmdleigx, 64.0 - 74.3)
Positive
05 Jun 2024
Phase 3
341
qyxjwtcihi(mcnhnqgzbj) = dmlpscypyo wtcubwjped (zzjkdpyynt )
Positive
05 Jun 2024
qyxjwtcihi(mcnhnqgzbj) = xxuofcmsrt wtcubwjped (zzjkdpyynt )
Not Applicable
-
Ixekizumab 80mg every 4 weeks
xnlhltygvi(nthwwdneec) = lbzmxmccod xxfdndgcyr (pekbucqgdv )
-
05 Jun 2024
Not Applicable
-
Ixekizumab 80 mg every 4 weeks
sqdskqzzrh(dnmvjljpmz) = hbhkosqxcg mkbnrykjii (kfjwftylzw )
-
05 Jun 2024
Placebo
sqdskqzzrh(dnmvjljpmz) = kmvmsxtuam mkbnrykjii (kfjwftylzw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free